Can You Keep Your Honeymoon Going? SAB Bio’s Clinical Trial for Newly Diagnosed Type 1 Patients

A new investigational medicine called SAB-142 is designed to help reduce or prevent loss of cells that produce insulin in the body. SAB Biotherapeutics is running the SAFEGUARD clinical study testing SAB-142 in people newly diagnosed with type 1 diabetes to see if it can prevent disease progression.

In this episode of Think Like a Pancreas—The Podcast, host Gary Scheiner sits down with SAB Biotherapeutics CEO, Sam Reicher to discuss what this study means for people with stage 2 and 3 type 1 diabetes, who can enroll, and why studies like these are so important.